ArticleFuture microbiology2017
Ldt
Article in Future microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Oral β-lactam combinations are effectiveMicrobiology spectrum · 2025Article
- Combinations comprising dual β-lactams and a β-lactamase inhibitor achieve optimal synergistic inhibition ofAntimicrobial agents and chemotherapy · 2025Article
- Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.The Journal of antimicrobial chemotherapy · 2024Review
- The use of dual β-lactams to restore susceptibility ofJAC-antimicrobial resistance · 2024Article
- Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model.International journal of antimicrobial agents · 2024Article
- β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.Antimicrobial agents and chemotherapy · 2021Article
- Select β-Lactam Combinations Exhibit Synergy againstAntimicrobial agents and chemotherapy · 2019Article
- Peptidoglycan in Mycobacteria: chemistry, biology and intervention.Glycoconjugate journal · 2018Review
- Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.Microbial drug resistance (Larchmont, N.Y.) · 2018Article
- Review
- Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.Antimicrobial agents and chemotherapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
aimMycobacterium avium infections, especially in immune-compromised individuals, present a significant challenge as therapeutic options are limited. In this study, we investigated if M. avium genome encodes nonclassical transpeptidases and if newer carbapenems are effective against this mycobacteria. MATERIALS &
methodsBiochemical and microbiological approaches were used to identify and characterize a nonclassical transpeptidase, namely L,D-transpeptidase, in M. avium. RESULTS &
conclusionWe describe the biochemical and physiological attributes of a L,D-transpeptidase in M. avium, Ldt
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.